Bluebird Bio completes sale pf PRV to Argenx

Following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, on December 29, bluebird bio completed the sale of a Rare Pediatric Disease Priority Review Voucher or PRV to Argenx . The Company was awarded the PRV under a U.S. Food and Drug Administration program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV when SKYSONA or elivaldogene autotemcel, received accelerated approval by the FDA to slow the progression of neurological dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy. The Asset Sale was pursuant to the terms of an Asset Purchase Agreement, dated November 29 , the material terms of which were previously disclosed by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 30 . Pursuant to the PRV Transfer Agreement, Buyer paid the Company $102M in cash upon the closing of the Asset Sale.